FIELD: medicine, gynecology.
SUBSTANCE: the present innovation deals with carrying out hormone-substitution therapy in women during menopause period or in sterilized women. For this purpose the above-mentioned therapy consists of the phase of relative dominant estrogen activity including three daytime dosages of a substance inducing estrogen activity being equivalent to approximately to 1 mg 17beta-estradiol daily, and the phase of relative dominant progestogen activity including combination of a substance inducing estrogen activity being equivalent to approximately 1 mg 17beta-estradiol daily and a substance that demonstrates progestogen activity being equivalent to approximately 90 mcg norgestimate daily. To fulfill such a therapy a pharmaceutical preparation is, also, suggested and a set of mentioned preparations. The innovation provides maximal weakening the symptoms of the disease, in particular, congestions along the safety of application due to decreased risk of known complications of estrogen therapy.
EFFECT: higher efficiency of therapy.
31 cl, 1 dwg, 1 ex, 2 tbl
Title | Year | Author | Number |
---|---|---|---|
SCHEME OF ESTROGEN REPLENISHMENT | 2003 |
|
RU2340345C2 |
CONTRACEPTION METHOD FOR BEING USED BY WOMEN OF REPRODUCTIVE PERIOD NOT ACCESSING PREMENOPAUSAL PERIOD | 1994 |
|
RU2169567C2 |
PHARMACEUTICAL COMBINED PREPARATION FOR HORMONAL CONTRACEPTION | 1995 |
|
RU2165258C2 |
PHARMACEUTICAL COMBINED PREPARATION FOR HORMONAL CONTRACEPTION | 1996 |
|
RU2165259C2 |
THREE-PHASE ORAL CONTRACEPTIVE | 1999 |
|
RU2225207C2 |
DROSPYRENON FOR REPLACEMENT HORMONOTHERAPY | 2001 |
|
RU2275198C2 |
DROSPIRENONE FOR HORMONAL REPLACEMENT THERAPY | 2005 |
|
RU2402331C2 |
PHARMACEUTICAL COMPOSITION CONTAINING TETRAHYDROFOLIC ACID | 2007 |
|
RU2479306C2 |
AGENT FOR HORMONAL CONTRACEPTION THAT INHIBITS OVULATION | 1992 |
|
RU2091069C1 |
PHARMACEUTICAL COMPOSITIONS CONTAINING DERIVATIVES OF ESTRA-1,3,5(10)-TRIENE | 1995 |
|
RU2179442C2 |
Authors
Dates
2005-02-10—Published
2000-03-22—Filed